Related Experiment Video
Updated: May 5, 2026
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.6K
Endocannabinoid signalling in Alzheimer's disease
Nazia Maroof1, Marie Christine Pardon, David A Kendall
1*Sheffield Institute for Translational Neuroscience (SITraN), 385a Glossop Road, University of Sheffield, Sheffield S10 2HQ, U.K.
Biochemical Society Transactions
|November 22, 2013
Summary
Endocannabinoids (ECs) and related lipids play roles in brain health, impacting neuroinflammation and neuroprotection. Research explores their potential in treating Alzheimer's disease by modulating these signaling systems.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Endocannabinoids (ECs) like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), along with related lipids N-oleoylethanolamide (OEA) and N-palmitoylethanolamide (PEA), are crucial signaling molecules.
- These lipids are involved in diverse physiological functions, including learning, memory, neuroinflammation, oxidative stress, neuroprotection, and neurogenesis.
- ECs and related lipids are implicated in the pathology and potential protective mechanisms of neurodegenerative diseases.
Purpose of the Study:
- To review the evidence for the involvement of endocannabinoids (ECs) in Alzheimer's disease (AD).
- To explore the therapeutic potential of manipulating the EC signaling system for AD treatment.
Main Methods:
- Literature review of existing research on ECs and Alzheimer's disease.
- Analysis of studies investigating the roles of AEA, 2-AG, OEA, and PEA in AD pathology and neuroprotection.
Main Results:
- ECs are implicated in key aspects of Alzheimer's disease, including neuroinflammation, oxidative stress, and neurodegeneration.
- Evidence suggests that modulating the EC system may offer neuroprotective benefits in AD.
Conclusions:
- The endocannabinoid system presents a promising target for novel therapeutic strategies against Alzheimer's disease.
- Further research into EC signaling pathways could lead to effective treatments for this common form of dementia.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:23Role of Neurotransmitters in Memory
2.8K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K